Combined effect of parthenolide and various anti-cancer drugs or anticancer candidate substances on malignant cells in vitro and in vivo

Mini-Reviews in Medicinal Chemistry

Volumn 14, Issue 3, 2014, Pages 222-228

  Wyrebska, Anna ^a   Gach, Katarzyna ^a   Janecka, Anna ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Anticancer drugs; Chemosensitivity; Chemotherapy; Metastasis; Nf b; Parthenolide

Indexed keywords

ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; BUTHIONINE SULFOXIMINE; CASPASE 3; CASPASE 9; CELECOXIB; CYCLOOXYGENASE 2; CYTOCHROME C; DACARBAZINE; DIMETHYLAMINOPARTHENOLIDE; FLUOROURACIL; FOLINIC ACID; GELDANAMYCIN; HEAT SHOCK PROTEIN 90; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 8; MANGANESE SUPEROXIDE DISMUTASE; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; OXALIPLATIN; PACLITAXEL; PARTHENOLIDE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN P53; REACTIVE OXYGEN METABOLITE; SULINDAC; SYNAPTOTAGMIN I; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; SESQUITERPENE;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CHEMOSENSITIVITY; COLORECTAL CANCER; CYTOTOXICITY; DNA BINDING; HUMAN; LUNG NON SMALL CELL CANCER; NONHUMAN; PANCREAS CANCER; PANCREAS TUMOR; TUMOR GROWTH; TUMOR VOLUME; ANIMAL; DRUG INTERACTION; NEOPLASM; PATHOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG INTERACTIONS; HUMANS; NEOPLASMS; SESQUITERPENES;

EID: 84896346940     PISSN: 13895575     EISSN: 18755607     Source Type: Journal    
DOI: 10.2174/1389557514666140219113509     Document Type: Article

References (78)

1. Heinrich, M., Robles, M.; West, J.E.; Ortiz de Montellano, B.R.; Rodriguez, E. Ethnopharmacology of Mexican asteraceae (Compositae). Annu. Rev. Pharmacol. Toxicol., 1998, 38, 539-565.
2. Janecka, A.; Wyrebska, A.; Gach, K.; Fichna, J.; Janecka, T. Natural and synthetic α-methylenelactones and α-methylenelactams with anticancer potential. Drug Discov. Today, 2012, 17(11-12), 561-572.
3. Zhang, S., Won, Y.K.; Ong, C.N.; Shen, H.M. Anti-cancer potential of sesquiterpene lactones: bioactivity and molecular mechanisms. Curr. Med. Chem. Anticancer Agents, 2005, 5(3), 239-249.
4. Koprowska, K.; Czyz, M. Molecular mechanisms of parthenolide's action: Old drug with a new face Postepy Hig. Med. Dosw. (Online)., 2010, 64, 100-114.
5. Hung, T.M.; Hung, T.M.; Na, M.; Dat, N.T.; Ngoc, T.M.; Youn, U.; Kim, H.J.; Min, B.S.; Lee, J.; Bae, K. Cholinesterase inhibitory and anti-amnesic activity of alkaloids from Corydalis turtschaninovii. J. Ethnopharmacol., 2008, 119(1), 74-80.
6. Wen, J.; You, K.R.; Lee, S.Y.; Song, C.H.; Kim, D.G. Oxidative stress-mediated apoptosis. The anticancer effect of the sesquiterpene lactone parthenolide. J. Biol. Chem., 2002, 277(41), 38954-38964.
7. Skalska, J.; Brookes, P.S.; Nadtochiy, S.M.; Hilchey, S.P.; Jordan, C.T.; Guzman, M.L.; Maggirwar, S.B.; Briehl, M.M.; Bernstein, S.H. Modulation of cell surface protein free thiols: a potential novel mechanism of action of the sesquiterpene lactone parthenolide. PLoS One, 2009, 4(12), e8115.
8. Liu, Z.; Liu, S.; Xie, Z.; Pavlovicz, R.E.; Wu, J.; Chen, P.; Aimiuwu, J.; Pang, J.; Bhasin, D.; Neviani, P.; Fuchs, J.R., Plass C., Li, P.K.; Li, C.; Huang, T.H.; Wu, L.C.; Rush, L.; Wang, H.; Perrotti, D.; Marcucci, G.; Chan, K.K. Modulation of DNA methylation by a sesquiterpene lactone parthenolide. J. Pharmacol. Exp. Ther., 2009, 329(2), 505-514.
9. Gao, Z.W.; Zhang, D.L.; Guo, C.B. Paclitaxel efficacy is increased by parthenolide via nuclear factor-kappaB pathways in in vitro and in vivo human non-small cell lung cancer models. Curr Cancer Drug Targets, 2010, 10(7), 705-715.
10. Fonrose, X.; Ausseil, F.; Soleilhac, E.; Masson, V.; David, B.; Pouny, I.; Cintrat, J.C.; Rousseau, B.; Barette, C.; Massiot, G.; Lafanechère, L. Parthenolide inhibits tubulin carboxypeptidase activity. Cancer Res., 2007, 67(7), 3371-3378.
11. Baldwin, A.S. Jr. The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu. Rev. Immunol., 1996, 14, 649-683.
12. Gosh S.; May M.J.; Kopp E.B.; NF-kappaB and Rel proteins: evolutionarily conserved mediators of immune responses. Annu. Rev. Immunol., 1998, 16, 225-260.
13. García-Piñeres A.J.; Castro, V.; Mora, G.; Schmidt, T.J.; Strunck, E.; Pahl, H.L.; Merfort, I. Cysteine 38 in p65/NF-kappaB plays a Anti-Cancer Drugs or Anti-Cancer Candidate Substances Tested in Combination Mini-Reviews in Medicinal Chemistry, 2014, Vol. 14, No. 3 227 crucial role in DNA binding inhibition by sesquiterpene lactones. J. Biol. Chem., 2001, 276(43), 39713-39720.
14. Kwok, B.H.; Koh, B.; Ndubuisi, M.I.; Elofsson, M.; Crews, CM. The anti-inflammatory natural product parthenolide from the medicinal herb Feverfew directly binds to and inhibits IkappaB kinase. Chem. Biol., 2001, 8, 759-766.
15. Ghantous, A.; Sinjab, A.; Herceg, Z.; Darwiche, N. Parthenolide: from plant shoots to cancer roots. Drug Discov. Today, 2013, 18(17-18), 894-905.
16. Sweeney, C.J.; Mehrotra, S.; Sadaria, M.R.; Kumar, S.; Shortle, N.H.; Roman, Y.; Sheridan, C.; Campbell, R.A.; Murry, D.J.; Badve, S.; Nakshatri, H. The sesquiterpene lactone parthenolide in combination with docetaxel reduces metastasis and improves survival in a xenograft model of breast cancer. Mol. Cancer Ther., 2005, 4(6), 1004-1012.
17. Neelakantan, S.; Nasim, S.; Guzman, M.L.; Jordan, C.T.; Crooks, P.A.Aminoparthenolides as novel anti-leukemic agents: Discovery of the NF-kappaB inhibitor, DMAPT (LC-1). Bioorg. Med. Chem. Lett., 2009, 19(15), 4346-4349.
18. Guzman, M.L.; Rossi, R.M.; Neelakantan, S.; Li, X.; Corbett, C.A.; Hassane, D.C.; Becker, M.W.; Bennett, J.M.; Sullivan, E.; Lachowicz, J.L.; Vaughan, A.; Sweeney, C.J.; Matthews, W.; Carroll, M.; Liesveld, J.L.; Crooks, P.A.; Jordan, C.T. An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells. Blood, 2007, 110(13), 4427-4435.
19. Shanmugam, R.; Kusumanchi, P.; Cheng, L.; Crooks, P.; Neelakantan, S.; Matthews, W.; Nakshatri, H.; Sweeney, C.J. A water-soluble parthenolide analogue suppresses in vivo prostate cancer growth by targeting NFkappaB and generating reactive oxygen species. Prostate, 2010, 70(10), 1074-1086.
20. Shanmugam, R.; Kusumanchi, P.; Appaiah, H.; Cheng, L.; Crooks, P.; Neelakantan, S.; Peat, T.; Klaunig, J.; Matthews, W.; Nakshatri, H.; Sweeney, C.J. A water soluble parthenolide analog suppresses in vivo tumor growth of two tobacco-associated cancers, lung and bladder cancer, by targeting NF-κB and generating reactive oxygen species. Int. J. Cancer, 2011, 128(10), 2481-2494.
21. Kevin, P. New agents for the treatment of leukemia: discovery of DMAPT (LC-1). Drug Disc. Today, 2010, 15, 322.
22. Oka, D.; Nishimura, K.; Shiba, M.; Nakai, Y.; Arai, Y.; Nakayama, M.; Takayama, H.; Inoue, H.; Okuyama, A., Nonomura, N. Sesquiterpene lactone parthenolide suppresses tumor growth in a xenograft model of renal cell carcinoma by inhibiting the activation of NF-kappaB. Int. J. Cancer, 2007, 120(12), 2576-2581.
23. Kishida, Y.; Yoshikawa, H.; Myoui, A. Parthenolide, a natural inhibitor of Nuclear Factor-kappaB, inhibits lung colonization of murine osteosarcoma cells. Clin. Cancer Res., 2007, 13(1), 59-67.
24. Mabuchi, S.; Ohmichi, M.; Nishio, Y.; Hayasaka, T.; Kimura, A.; Ohta, T.; Kawagoe, J.; Takahashi, K.; Yada-Hashimoto, N.; Seino- Noda, H.; Sakata, M.; Motoyama, T.; Kurachi, H.; Testa, J.R.; Tasaka, K.; Murata, Y. Inhibition of inhibitor of nuclear factor-κB phosphorylation increases the efficacy of taxol in in vitro and in vivo ovarian cancer models. Clin. Cancer Res., 2004, 10(22), 7645-7654.
25. Fujioka, S.; Sclabas, G.M.; Schmidt, C.; Frederick, W.A.; Dong, Q.G.; Abbruzzese, J.L.; Evans, D.B.; Baker, C.; Chiao, P.J. Function of nuclear factor kappaB in pancreatic cancer metastasis. Clin. Cancer Res., 2003, 9(1), 346-354.
26. Montagut, C.; Tusquets, I.; Ferrer, B.; Corominas, J.M.; Bellosillo, B.; Campas, C.; Suarez, M.; Fabregat, X.; Campo, E.; Gascon, P.; Serrano, S.; Fernandez, L.; Rovira, A.; Albanell, J. Activation of nuclear factor-κB is linked to resistance to neoadjuvant chemotherapy in breast cancer patients. Endocr. Relat. Cancer, 2006, 13(2), 607-616.
27. Fradet, V.; Lessard, L.; Bégin, L.R.; Karakiewicz, P.; Masson, A.M.; Saad, F. Nuclear factor-kappaB nuclear localization is predictive of biochemical recurrence in patients with positive margin prostate cancer. Clin. Cancer Res., 2004, 10(24), 8460-8464.
28. Bork, P.M.; Schmitz, M.L.; Kuhnt, M.; Escher, C.; Heinrich, M. Sesquiterpene lactone containing Mexican Indian medicinal plants and pure sesquiterpene lactones as potent inhibitors of transcription factor NF-kappaB. FEBS Lett., 1997, 402(1), 85-90.
29. Huang, Y.; Johnson, K.R.; Norris, J.S.; Fan, W. Nuclear factor - kB/IkB signaling pathway may contribute to the mediation of paclitaxel-induced apoptosis in solid tumor cells. Cancer Res., 2000, 60(16), 4426-4432.
30. Boland, M.; Fitzgerald, K.A.; O'Neill, L.A.J. Topoisomerase II is required for mitoxantrone to signal nuclear factor kB activation in HL60 cells. J. Biol. Chem., 2000, 275(33), 25231-25238.
31. Patel, N.M.; Nozaki, S.; Shortle, N.H.; Bhat-Nakshatri, P.; Newton, T.R.; Rice, S.; Gelfanov, V.; Boswell, S.H.; Goulet, R.J. Jr.; Sledge, G.W. Jr.; Nakshatri, H. Paclitaxel sensitivity of breast cancer cells with constitutively active NF-kappaB is enhanced by IkappaBalpha super-repressor and parthenolide. Oncogene., 2000, 19(36), 4159-4169.
32. Wang, C.Y.; Cusack, J.C. Jr.; Liu, R.; Baldwin, A.S. Jr. Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaB. Nat. Med., 1999, 5(4), 412-417.
33. Zhang, D.; Qiu, L.; Jin, X.; Guo, Z.; Guo, C. Nuclear factorkappaB inhibition by parthenolide potentiates the efficacy of Taxol in non-small cell lung cancer in vitro and in vivo. Mol. Cancer Res., 2009, 7(7), 1139-1149.
34. Dy, G.K.; Thomas, J.P.; Wilding, G.; Bruzek, L.; Mandrekar, S.; Erlichman, C.; Alberti, D.; Binger, K.; Pitot, H.C.; Alberts, S.R.; Hanson, L.J.; Marnocha, R.; Tutsch, K.; Kaufmann, S.H.; Adjei, A.A. A phase I and pharmacologic trial of two schedules of the proteasome inhibitor, PS-341 (bortezomib, velcade), in patients with advanced cancer. Clin. Cancer Res., 2005, 11(9), 3410-3416.
35. Karin, M.; Yamamoto, Y.; Wang, Q.M. The IKK NF-κB system: a treasure trove for drug development. Nat. Rev. Drug Discov., 2004, 3(1), 17-26.
36. Meyerhardt, J.A.; Mayer, R.J. Systemic therapy for colorectal cancer. N. Engl. J. Med., 2005, 352(5), 476-487.
37. Tebbutt, N.C.; Cattell, E.; Midgley, R.; Cunningham, D.; Kerr, D. Systemic treatment of colorectal cancer. Eur. J. Cancer, 2002, 38(7), 1000-1015.
38. Kuhn, J.G. Fluorouracil and the new oral fluorinated pyrimidines. Ann. Pharmacother., 2001, 35(2), 217-227.
39. Kim, S.L.; Trang, K.T.; Kim, S.H.; Kim, I.H.; Lee, S.O.; Lee, S.T.; Kim, D.G.; Kim, S.W. Parthenolide suppresses tumor growth in a xenograft model of colorectal cancer cells by inducing mitochondrial dysfunction and apoptosis. Int. J. Oncol., 2012, 41(4), 1547-1553.
40. Kim, S.L.; Kim, S.H.; Trang, K.T.; Kim, I.H.; Lee, S.O.; Lee, S.T.; Kim, D.G.; Kang, S.B.; Kim, S.W. Synergistic antitumor effect of 5-fluorouracil in combination with parthenolide in human colorectal cancer. Cancer Lett., 2013, 335(2), 479-486.
41. Fearon, E.R.; Vogelstein, B. A genetic model for colorectal tumorigenesis, Cell, 1990, 61(5), 759-767.
42. Yip-Schneider, M.T.; Barnard, D.S.; Billings, S.D.; Cheng, L.; Heilman, D.K.; Lin, A.; Marshall, S.J.; Crowell, P.L.; Marshall, M.S.; Sweeney, C.J. Cyclooxygenase-2 expression in human pancreatic adenocarcinomas. Carcinogenesis, 2000, 21(2), 139-146.
43. Yip-Schneider, M.T.; Sweeney, C.J.; Jung, S.H.; Crowell, P.L.; Marshall, M.S. Cell cycle effects of nonsteroidal anti-inflammatory drugs and enhanced growth inhibition in combination with gemcitabine in pancreatic carcinoma cells. J. Pharmacol. Exp. Ther., 2001, 298(3), 976-985.
44. Yip-Schneider, M.T.; Nakshatri, H.; Sweeney, C.J.; Marshall, M.S.; Wiebke, E.A.; Schmidt, C.M. Parthenolide and sulindac cooperate to mediate growth suppression and inhibit the nuclear factor-kappa B pathway in pancreatic carcinoma cells. Mol. Cancer Ther., 2005, 4(4), 587-594.
45. Martin, S.S.; Ridgeway, A.G.; Pinkas J.; Lu, Y.; Reginato, M.J.; Koh, E.Y.; Michelman, M.; Daley, G.Q.; Brugge, J.S.; Leder, P.; A cytoskeleton-based functional genetic screen identifies Bcl-xL as an enhancer of metastasis, but not primary tumor growth. Oncogene, 2004, 23(26), 4641-4645.
46. Yip-Schneider, M.T.; Wu, H.; Ralstin, M.; Yiannoutsos, C.; Crooks, P.A.; Neelakantan, S.; Noble, S.; Nakshatri, H.; Sweeney, C.J.; Schmidt, C.M. Suppression of pancreatic tumor growth by combination chemotherapy with sulindac and LC-1 is associated with cyclin D1 inhibition in vivo. Mol. Cancer Ther., 2007, 6(6), 1736-1744.
47. Wang, W.; Abbruzzese, J.L.; Evans, D.B.; Larry, L.; Cleary, K.R.; Chiao, P.J.; The nuclear factor-kappa B RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells. Clin. Cancer Res., 1999, 5(1), 119-127.
48. Yip-Schneider, M.T.; Barnard, D.S.; Billings, S.D.; Cheng, L.; Heilman, D.K.; Lin, A.; Marshall, S.J.; Crowell, P.L.; Marshall M.S.; Sweeney C.J.; Cyclooxygenase-2 expression in human pancreatic adenocarcinomas. Carcinogenesis, 2000, 21(2), 139-146.
49. Yip-Schneider, M.T.; Wu, H.; Njoku, V.; Ralstin, M.; Holcomb, B.; Crooks, P.A.; Neelakantan, S.; Sweeney, C.J.; Schmidt, C.M. Effect of celecoxib and the novel anti-cancer agent, dimethylamino-parthenolide, in a developmental model of pancreatic cancer. Pancreas, 2008, 37(3), e45-53.
50. Bae, S.H.; Jung, E.S.; Park, Y.M., Kim, B.S.; Kim, B.K.; Kim, D.G., Ryu, W.S. Expression of cyclooxygenase-2 (COX-2) in hepatocellular carcinoma and growth inhibition of hepatoma cell lines by a COX-2 inhibitor, NS-398. Clin. Cancer Res., 2001, 7(5), 1410-1418.
51. Koga, H.; Sakisaka, S.; Ohishi, M.; Kawaguchi, T.; Taniguchi, E.; Sasatomi, K.; Harada, M.; Kusaba, T.; Tanaka, M.; Kimura, R.; Nakashima, Y.; Nakashima, O.; Kojiro, M.; Kurohiji, T.; Sata, M. Expression of cyclooxygenase-2 in human hepatocellular carcinoma: relevance to tumor dedifferentiation. Hepatology, 1999, 29(3), 688-696.
52. Shiota, G.; Okubo, M.; Noumi, T.; Noguchi, N.; Oyama, K.; Takano, Y.; Yashima, K.; Kishimoto, Y.; Kawasaki, H. Cyclooxygenase-2 expression in hepatocellular carcinoma. Hepatogastroenterology., 1999, 46(25), 407-412.
53. Kern, M.A.; Schubert, D.; Sahi, D.; Schöneweiss, M.M.; Moll I.; Haugg, A.M.; Dienes, H.P.; Breuhahn, K.; Schirmacher, P. Proapoptotic and antiproliferative potential of selective cyclooxygenase-2 inhibitors in human liver tumor cells. Hepatology, 2002, 36(4 Pt 1), 885-894.
54. Ralstin, M.C.; Gage, E.A.; Yip-Schneider, M.T.; Klein, P.J.; Wiebke, E.A.; Schmidt, C.M. Parthenolide cooperates with NS398 to inhibit growth of human hepatocellular carcinoma cells through effects on apoptosis and G0-G1 cell cycle arrest. Mol. Cancer Res., 2006, 4(6), 387-399.
55. Whitesell, L.; Lindquist, S.L. HSP90 and the chaperoning of cancer. Nat. Rev. Cancer., 2005, 5(10), 761-772.
56. Moser C.; Lang S.A.; Stoeltzing O.; Heat-shock protein 90 (Hsp90) as a molecular target for therapy of gastrointestinal cancer. Anticancer Res., 2009, 29(6), 2031-2042.
57. Reikvam, H.; Ersvaer, E.; Bruserud, O. Heat shock protein 90 - a potential target in the treatment of human acute myelogenous leukemia. Curr. Cancer Drug Targets., 2009, 9(6), 761-776.
58. Whitesell L.; Lindquist S.L.; HSP90 and the chaperoning of cancer. Nat. Rev. Cancer., 2005, 5(10), 761-772.
59. Hwang, M.; Moretti, L.; Lu, B. HSP90 inhibitors: multi-targeted antitumor effects and novel combinatorial therapeutic approaches in cancer therapy. Curr. Med. Chem., 2009, 16(24), 3081-3092.
60. Lee, C.S.; Kim, Y.J.; Lee, S.A.; Myung, S.C.; Kim, W. Combined effect of Hsp90 inhibitor geldanamycin and parthenolide via reactive oxygen species-mediated apoptotic process on epithelial ovarian cancer cells. Basic Clin. Pharmacol. Toxicol., 2012, 111(3), 173-181.
61. Antman, K.H. Introduction: the history of arsenic trioxide in cancer therapy. Oncologist., 2001, 6 Suppl 2, 1-2.
62. Shen, Z.X.; Chen, G.Q.; Ni, J.H. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood, 1997, 89(9), 3354-3360.
63. Yang, C.H.; Kuo, M.L.; Chen, J.C.; Chen, Y.C. Arsenic trioxide sensitivity is associated with low level of glutathione in cancer cells. Br. J. Cancer., 1999, 81(5), 796-799.
64. Zhou, L.; Jing, Y.; Styblo, M.; Chen, Z.; Waxman, S. Glutathione- S-transferase pi inhibits As2O3-induced apoptosis in lymphoma cells: involvement of hydrogen peroxide catabolism. Blood, 2005, 105(3), 1198-1203.
65. Davison, K.; Côté, S.; Mader, S.; Miller, W.H. Glutathione depletion overcomes resistance to arsenic trioxide in arsenicresistant cell lines. Leukemia, 2003, 17(5), 931-940.
66. Hu, X.M.; Hirano, T.; Oka, K. Arsenic trioxide induces apoptosis in cells of MOLT-4 and its daunorubicin-resistant cell line via depletion of intracellular glutathione, disruption of mitochondrial membrane potential and activation of caspase-3. Cancer Chemother. Pharmacol., 2003, 52(1), 47-58.
67. Tabellini, G.; Cappellini, A.; Tazzari, P.L.; Fala, F.; Billi, A.M.; Manzoli, L.; Cocco, L.; Martelli, A.M. Phosphoinositide 3- kinase/Akt involvement in arsenic trioxide resistance of human leukemia cells. J. Cell Physiol., 2005, 202(2), 623-634.
68. Felix, K.; Manna, S.K.; Wise, K.; Barr, J.; Ramesh, G.T. Low level of arsenite activates nuclear factor-kappaB and activator protein-1 in immortalized mesencephalic cells. J. Biochem. Mol. Tox., 2005, 19(2), 67-77.
69. Zhou, L.; Jing, Y.; Styblo, M.; Chen, Z.; Waxman, S. Glutathione- S-transferase pi inhibits As2O3-induced apoptosis in lymphoma cells: involvement of hydrogen peroxide catabolism. Blood.,2005, 105(3), 1198-1203.
70. Kerbauy, D.M.; Lesnikov, V.; Abbasi, N.; Seal, S.; Scott, B.; Deeg, H.J. NF-kB and FLIP in arsenic trioxide (ATO)-induced apoptosis in myelodysplastic syndromes (MDSs). Blood, 2005, 106(12), 3917-3925.
71. Lemarie, A.; Morzadec, C.; Merino, D.; Micheau, O.; Fardel, O.; Vernhet, L. Arsenic trioxide induces apoptosis of human monocytes during macrophagic diVerentiation through nuclear factor-kappaB-related survival pathway down-regulation. J. Pharmacol. Exp. Ther., 2006, 316(1), 304-314.
72. Mathas, S.; Lietz, A.; Janz, M.; Hinz, M.; Jundt, F.; Scheidereit, C.; Bommert, K.; Dorken, B. Inhibition of NF-kappaB essentially contributes to arsenic-induced apoptosis. Blood.,2003, 102(3), 1028-1034.
73. Kapahi, P.; Takahashi, T.; Natoli, G.; Adams, S.R.; Chen, Y.; Tsien, R.Y.; Karin, M. Inhibition of NF-kappa B activation by arsenite through reaction with a critical cysteine in the activation loop of Ikappa B kinase. J. Biol. Chem., 2000, 275(46), 36062-36066.
74. Wang, W.; Adachi, M.; Zhang, R.; Zhou, J.; Zhu, D. A novel combination therapy with arsenic trioxide and parthenolide against pancreatic cancer cells. Pancreas, 2009, 38(4), 114-123.
75. Duechler, M.; Stanczyk, M.; Czyz, M.; Stepnik, M. Potentiation of arsenic trioxide cytotoxicity by Parthenolide and buthionine sulfoximine in murine and human leukemic cells. Cancer Chemother. Pharmacol., 2008, 61(5), 727-737.
76. Lev, D.C.; Ruiz, M.; Mills, L.; McGary, E.C.; Price, J.E.; Bar-Eli, M. Dacarbazine causes transcriptional up-regulation of interleukin 8 and vascular endothelial growth factor in melanoma cells: a possible escape mechanism from chemotherapy. Mol. Cancer Ther., 2003, 2(8), 753-763.
77. Koprowska, K.; Hartman, M.L.; Sztiller-Sikorska, M.; Czyz, M.E. Parthenolide enhances dacarbazine activity against melanoma cells. Anticancer Drugs, 2013, 24(8), 835-845.
78. Fang, L.J.; Shao, X.T.; Wang, S.; Lu, G.H.; Xu, T.; Zhou, J.Y. Sesquiterpene lactone parthenolide markedly enhances sensitivity of human A549 cells to low-dose oxaliplatin via inhibition of NFkappaB activation and induction of apoptosis. Planta Med., 2010, 76(3), 258-264.